{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:17:40Z","timestamp":1790399860061,"version":"4.1.0"},"reference-count":81,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T00:00:00Z","timestamp":1207785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Novel strategies are required for treatment of acute myeloid leukaemia (AML) and higher risk myelodysplastic syndrome (MDS) patients who are not eligible for intensive chemotherapy and\/or allogenic stem cell transplantation. As activating <jats:italic>RAS<\/jats:italic> mutations are frequent in these diseases, one novel approach, consisting of interfering with isoprenylation of RAS proteins by farnesyltransferase inhibitors (FTIs), has been proposed. Clinical phase II studies with the oral FTIs tipifarnib and lonafarnib in previously untreated AML, MDS and chronic myelomonocytic leukaemia yielded rather encouraging results while results in relapsed and\/or refractory AML were disappointing. Results of a phase III trial in untreated AML in the elderly with tipifarnib were also disappointing. Clinical responses were not related to <jats:italic>RAS<\/jats:italic> mutations, suggesting additional actions of FTIs on other molecular targets. The combination of existing FTIs with other treatments, such as chemotherapy (in AML) and hypomethylating agents (in MDS and AML), is under investigation. Ongoing studies will also determine if gene profiling analysis may help to identify patients that will respond to FTIs.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07099.x","type":"journal-article","created":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T18:24:52Z","timestamp":1207851892000},"page":"576-586","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia"],"prefix":"10.1111","volume":"141","author":[{"given":"Thorsten","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.2046"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.1.85"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R500012-JLR200"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/366643a0"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21590"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.4.1237.1237"},{"key":"e_1_2_8_8_1","first-page":"5656","article-title":"Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations","volume":"63","author":"Brunner T.B.","year":"2003","journal-title":"Cancer Research"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403569"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(96)80060-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1016\/S0021-9258(18)98665-5","article-title":"Interaction of the regulatory subunit (RII) of cAMP\u2010dependent protein kinase with RII\u2010anchoring proteins occurs through an amphipathic helix binding motif","volume":"266","author":"Carr D.W.","year":"1991","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.21.8323"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.040"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0764-7"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.005"},{"key":"e_1_2_8_16_1","first-page":"2589","article-title":"The BCR\u2010ABL tyrosine kinase inhibits apoptosis by activating a Ras\u2010dependent signaling pathway","volume":"13","author":"Cortez D.","year":"1996","journal-title":"Oncogene"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-419X(97)00011-5"},{"key":"e_1_2_8_18_1","first-page":"388","article-title":"Farnesyltransferase inhibitors: promises and realities","volume":"2","author":"Cox A.D.","year":"2002","journal-title":"Current Opinion in Chemical Biology"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006213200"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401023"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_8_22_1","first-page":"5492","article-title":"Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors","volume":"59","author":"Du W.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.3.1831"},{"key":"e_1_2_8_24_1","first-page":"131","article-title":"Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro","volume":"61","author":"End D.W.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.01.097"},{"key":"e_1_2_8_26_1","first-page":"1531a","article-title":"Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome","volume":"102","author":"Feldman EJ","year":"2003","journal-title":"Blood"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035725"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"810a","DOI":"10.1182\/blood.V110.11.817.817","article-title":"Azacitidine (AZA) treatment prolongs overall survival (OS) in higher\u2010risk MDS patients compared with conventional care regimens (CCR): results of the AZA\u2010001 phase III study","volume":"110","author":"Fenaux P.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009142"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1367-5931(98)80034-3"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(01)00220-0"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90294-O"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046144"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"439a","DOI":"10.1182\/blood.V110.11.439.439","article-title":"A randomized phase 3 study of tipifarnib compared to best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70\u2003years or older","volume":"110","author":"Harousseau J.L.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0687"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.9.4454"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.1.139-148.2000"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3361"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403413101"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb09404.x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00336.x"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3359"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.082"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-014357"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm970226l"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.16.6105-6113.2000"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.62.070193.004223"},{"key":"e_1_2_8_49_1","first-page":"1763","article-title":"Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells","volume":"10","author":"Manne V.","year":"1995","journal-title":"Oncogene"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0248"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.6.1823"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403022"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.1276"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.6.1603.bloodjournal8361603"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02472.x"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401044"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.2.590.590"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0778"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32108"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<283::AID-IJC22>3.0.CO;2-6"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.037"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-4-56"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2609"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90242-7"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1655"},{"key":"e_1_2_8_66_1","first-page":"7507","article-title":"Preclinical antitumor activity of BMS\u2010214662, a highly apoptotic and novel farnesyltransferase inhibitor","volume":"61","author":"Rose W.C.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.22.14093"},{"key":"e_1_2_8_68_1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1042\/bst0240692","article-title":"Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs","volume":"24","author":"Sebti S.M.","year":"1996","journal-title":"Biochemical Society Transactions"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.12.2767"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.32.20243"},{"key":"e_1_2_8_71_1","first-page":"5302","article-title":"A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage\u2010dependent and \u2010independent growth of human tumor cell lines","volume":"55","author":"Sepp\u2010Lorenzino L.","year":"1995","journal-title":"Cancer Research"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403274"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078576"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.26.15356"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(93)90072-U"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.112"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.22.14459"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.956"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgi341"},{"key":"e_1_2_8_82_1","first-page":"450","article-title":"Farnesyltransferase inhibitors reverse Ras\u2010mediated inhibition of Fas gene expression","volume":"62","author":"Zhang B.","year":"2002","journal-title":"Cancer Research"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07099.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07099.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:50:40Z","timestamp":1697406640000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07099.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,15]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07099.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07099.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,15]]},"assertion":[{"value":"2008-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}